Home › Studies › PRJEB122858
PRJEB122858 ERP202873

Gut metagenomes, IBD vs healthy, Israel, case-control

Disrupted Terminal Bilirubin Catabolism Links Lachnospiraceae Depletion to Inflammatory Bowel Disease

Fecal shotgun metagenomes from 124 samples (119 adult participants: Crohn's disease, ulcerative colitis, and healthy controls) in Israel, in a case-control study examining bilirubin catabolism and Lachnospiraceae depletion in IBD. machine-written summary

124 samples · 124 runs · IL · Age unknown · 2026 · 0.47 Gbp / sample

Sources
✓Sequence archive 744○Abstract / description✓Full text 124✓Supplementary tables 540–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive744 sample values (collection date, country, latitude, location region, longitude, subject id)
○ Abstract / descriptionread; no usable statement
✓ Full text124 sample values (antibiotic exposure) · PMC13526984
✓ Supplementary tables540 sample values (age, health condition, health condition detail, sex, smoking status)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Samples at a glance
1 sampling locations · 1 country
Age
adult121
elderly3
Condition
healthy_control49
crohns_disease43
ulcerative_colitis32
Sex
female68
male54
Country
IL124
Body site
primary124
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)this project, 0.03–0.1 Gbp: 3 samplesall projects, 0.1–0.3 Gbp: 29,179 samples (5 %)this project, 0.1–0.3 Gbp: 9 samplesall projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 112 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)all projects, 3–10 Gbp: 253,728 samples (44 %)all projects, 10–30 Gbp: 72,533 samples (13 %)all projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 0.47 Gbp per sample0130Gbp
Community composition

No Sandpiper profile for this project's samples yet.

Field coverage
fieldsamplescoverageR1R2R3R4
age_category124 100%
country124 100%124
health_condition124 100%124
subject_id124 100%124
antibiotic_exposure124 100%124
collection_date124 100%124
detailed_location124 100%
health_condition_detail124 100%124
latitude124 100%124
location_region124 100%124
longitude124 100%124
sex122 98%122
age_at_collection_days112 90%112
smoking_status58 47%58
Papers (1)
  • Disrupted terminal bilirubin catabolism links <i>Lachnospiraceae</i> depletion to inflammatory bowel disease. 2026 PMID 42676636 PMC13526984 own_data
Details
Archive description

The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown. Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn's disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD). We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted (p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels. These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family's known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective 2 properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.75. Assay shotgun_dna.

  • host run.host_tax_id · “9606”
  • host run.scientific_name · “human gut metagenome”
  • body site study.description · “fecal samples from 119 participants”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMEA123307372age_at_collection_days12053.0R20.80paper.supp.Table_1.XLSX[Table S1 Clinical Informatiom][Age]33
SAMEA123307372antibiotic_exposurenoR30.70paper.fulltext.methodsantibiotic use within 4 weeks of collection
SAMEA123307372collection_date2022R10.90biosample.attribute:collection_date2022
SAMEA123307372countryILR10.90sample.attr.geographic_location_country_and_or_seaIsrael
SAMEA123307372health_conditionhealthy_controlR20.80paper.supp.Table_1.XLSX[Table S1 Clinical Informatiom][Group]Healthy
SAMEA123307372health_condition_detailHealthyR20.80paper.supp.Table_1.XLSX[Table S1 Clinical Informatiom][Group]Healthy
SAMEA123307372latitude31.2589R10.90biosample.attribute:geographic_location_latitude+geographic_location_longitude31.2589 34.8014
SAMEA123307372location_regionSouthern DistrictR10.60biosample.attribute:geographic_location_latitude+geographic_location_longitude31.2589 34.8014
SAMEA123307372longitude34.8014R10.90biosample.attribute:geographic_location_latitude+geographic_location_longitude31.2589 34.8014
SAMEA123307372sexfemaleR20.80paper.supp.Table_1.XLSX[Table S1 Clinical Informatiom][Gender]F
SAMEA123307372smoking_statusneverR20.80paper.supp.Table_1.XLSX[Table S1 Clinical Informatiom][Smoking]no
SAMEA123307372subject_idGUT1R10.85sample.attr.host_subject_idGUT1
Sequencing

124 runs over 124 samples · mean 0.45 Gbp per run (median 0.47 Gbp, total 56.12 Gbp; 124 runs with a base count) · layout SINGLE 124 · platform ILLUMINA 124 · models Illumina NovaSeq 6000 (124) · 0% of runs with a Sandpiper profile · first public 2026-08-13

Authors (13)

Sabti O first · Lialin-Tzadikov K · Ivanova V · Dori-Bachash M · Uzi-Gavrilov S · Tik Z · Mashiach R · Zorea A · Mizrahi I · Segal A · Moyal-Attias K · Elinav E · Meijler MM last

Downloads

PRJEB122858.csv.gz (4.6 KB) · parquet (76.5 KB) — all 124 samples, every field with route and confidence · PRJEB122858_determinations.csv.gz (9.4 KB) — 1,408 evidence rows

Samples (124 · every field this project has values for · hover a cell for its source)
Loading the sample table…